Verona Pharma PLC Total Voting Rights & Block Listing Interim Review (6715W)
February 13 2017 - 2:00AM
UK Regulatory
TIDMVRP
RNS Number : 6715W
Verona Pharma PLC
13 February 2017
Verona Pharma plc
("Verona Pharma" or the "Company")
Total Voting Rights
Block Listing Interim Review
13 February 2017, London - Verona Pharma plc (AIM: VRP), a
clinical-stage biopharmaceutical company focused on developing and
commercialising innovative therapeutics for the treatment of
respiratory diseases with significant unmet medical needs,
announces an update to its total voting rights and a block listing
interim review.
The Company confirms that, following the 50 for 1 share
consolidation approved by shareholders on 8 February 2017, Verona
Pharma now has 51,361,064 ordinary shares of GBP0.05 each
("Ordinary Shares") in issue, each carrying one voting right. The
Company has no shares in treasury. Accordingly the figure of
51,361,064 may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
Company under the FCA's Disclosure Guidance and Transparency
Rules.
From 8:00 a.m. today, the Company's shares will trade under ISIN
GB00BYW2KH80 and SEDOL number BYW2KH8.
Verona Pharma has a block listing issued in respect of Ordinary
Shares which may arise pursuant to the exercise of warrants issued
in connection with the placing completed in July 2016 ("Warrant
Shares"). An interim update is included below for the purposes of
AIM Rule 29, confirming that there are 10,262,879 of the newly
consolidated Ordinary Shares which are currently block listed.
Name of applicant: Verona Pharma plc
-------------------------------------------------------------------- ------------------------------------------------
Name of scheme: 2016 Warrant Shares
-------------------------------------------------------------------- ------------------------------------------------
Period of return: From: 1 August 2016 To: 10 February 2017
------------------------------------- ----------------------------- ----------------- ------- --------------------
Balance of unallotted securities under scheme(s) from previous (1) Pre consolidation: 513,143,965
return: (2) Post consolidation: 10,262,879
-------------------------------------------------------------------- ------------------------------------------------
Plus: The amount by which the block scheme(s) has been increased (2) Nil
since the date of the last
return (if any increase has been applied for):
-------------------------------------------------------------------- ------------------------------------------------
Less: Number of securities issued/allotted under scheme(s) (2) Nil
during period:
-------------------------------------------------------------------- ------------------------------------------------
Less: Number of options over securities which have now lapsed: (2) Nil
-------------------------------------------------------------------- ------------------------------------------------
Equals: Balance under schemes not yet issued/allotted at end of
period: (2) 10,262,879
-------------------------------------------------------------------- ------------------------------------------------
Number and class of securities originally admitted: (1) Pre consolidation: 513,143,965
(2) Post consolidation: 10,262,879
-------------------------------------------------------- -----------------------------------------
Dates of admission: (1) 29 July 2016
(2) 13 February 2017
-------------------------------------------------------- -----------------------------------------
Name of contact: Piers J Morgan
-------------------------------------------------------- -----------------------------------------
Telephone number of contact: +44 (0)20 3283 4200
-------------------------------------------------------- -----------------------------------------
-Ends-
For further information please contact:
Verona Pharma plc Tel: +44 (0)20 3283
4200
Jan-Anders Karlsson, Chief
Executive Officer
N+1 Singer (Nominated Adviser Tel: +44 (0)20 7496
and UK Broker) 3000
Aubrey Powell / James White
FTI Consulting Tel: +44 (0)20 3727
1000
Simon Conway / Stephanie Cuthbert
/
Natalie Garland-Collins
Notes to Editors
About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company
focused on developing and commercialising innovative therapeutics
for the treatment of respiratory diseases with significant unmet
medical needs.
Verona Pharma's product candidate, RPL554, is a first-in-class,
inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4
that acts as both a bronchodilator and an anti--inflammatory agent
in a single compound. In clinical trials, treatment with RPL554 has
been observed to result in statistically significant improvements
in lung function as compared to placebo and has shown clinically
meaningful and statistically significant improvements in lung
function when added to two commonly used bronchodilators as
compared to either bronchodilator administered as a single agent.
Verona Pharma is developing RPL554 for the treatment of chronic
obstructive pulmonary disease (COPD), cystic fibrosis, and
potentially asthma.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVRMMGMZZZDGNZZ
(END) Dow Jones Newswires
February 13, 2017 02:00 ET (07:00 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024
